Steven E. Nissen, MD, FACC Cleveland, Ohio CLASSICAL INVASIVE VERSUS CONSERVATIVE TRIALS
|
|
- Maximilian Harvey
- 5 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN /03/$30.00 Published by Elsevier Science Inc. doi: /s (02) Pathobiology, Not Angiography, Should Guide Management in Acute Coronary Syndrome/ Non ST-Segment Elevation Myocardial Infarction The Non-Interventionist s Perspective Steven E. Nissen, MD, FACC Cleveland, Ohio Although an early invasive strategy (angiography and percutaneous coronary intervention) is the convention in acute coronary syndrome (ACS)/non ST-segment elevation myocardial infarction (MI) in the U.S., a conservative pharmacologic approach is common in other countries. Trial evidence has demonstrated a modest benefit with an angiographically guided approach; but patients having negative troponin values or who were receiving aspirin showed little or no benefit, and those without ST-segment changes had slightly worse outcomes. Limitations of angiography are clinically important. Identification of hemodynamically significant stenoses may be confounded by coronary remodeling. Also, most plaques, particularly those responsible for acute events, are extraluminal. Assessment of the luminal diameter of a lesion, which requires comparison with a normal reference segment, may be impossible because of the diffuse nature of the disease. Percutaneous coronary intervention after plaque rupture may itself cause embolization and no-reflow phenomena, leading to severe complications. In addition, most ruptures may be clinically silent. Evidence of a systemic inflammatory component suggests that ACS patients are at risk for plaque rupture at multiple sites. The inability of angiography to depict the true extent of atherosclerosis is supported by necropsy and transplant donor studies. A metabolic approach to this systemic disease is the only strategy designed to influence the behavior of both the small number of angiographically visible lesions and the large number of occult plaques. Statins and other agents decrease the incidence of death and MI by stabilizing atherosclerotic plaques throughout the coronary bed, reducing inflammation, collagen degradation, tissue factor expression, and vasomotor tone. (J Am Coll Cardiol 2003;41:103S 112S) 2003 by the American College of Cardiology Foundation Please refer to the Trial Appendix at the back of this supplement for the complete list of Clinical Trials. From the Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio. Dr. Nissen has been a consultant for Pfizer, Merck & Co., Astra Zeneca, Sankyo, and Takeda Pharmaceuticals. Manuscript received July 9, 2002; revised manuscript received October 9, 2002, accepted October 31, Hospital admissions for acute coronary syndrome (ACS) or non ST-segment elevation myocardial infarction (NSTEMI) occur in more than 1.4 million patients annually in the U.S. (1996 data) (1), but the optimal approach to its management remains controversial. In most American tertiary care centers, ACS patients are managed using an aggressive early invasive strategy, defined as angiography and percutaneous coronary intervention (PCI) within a few hours to a few days after presentation. However, most practice patterns and guidelines outside the U.S. promote an initial early conservative approach that uses anti-ischemic, anti-platelet, and anti-thrombotic drug therapy while they reserve urgent angiography and intervention for high-risk patients or those with refractory symptoms. With this approach, clinically stable patients undergo functional testing to stratify them for elective coronary angiography. Advances in medical and interventional care have made comparison studies of conservative versus aggressive strategies difficult to interpret (2 8). Key advances in PCI include stenting with adjunctive use of glycoprotein (GP) IIb/IIIa inhibitors. Advances in medical therapy include GP IIb/IIIa inhibitors and/or clopidogrel, low-molecular-weight heparins, and aggressive use of lipid-lowering agents. Few trials have made comparisons between angiographically guided management and optimal medical therapy; however, a review of existing trials and an understanding of the pathophysiology of ACS provide a reasonable basis for making decisions. This review provides the rationale for approaching ACS as a systemic disease, rather than focusing on identification and interventional treatment of the focal stenosis. CLASSICAL INVASIVE VERSUS CONSERVATIVE TRIALS The scientific case for an angiographically guided approach to ACS is not particularly well supported by traditional clinical trials, despite its popularity in the U.S. Before the development of stenting and GP IIb/IIIa inhibitors, the Thrombolysis In Myocardial Infarction (TIMI) IIIB study randomized 1,473 patients with unstable angina or NSTEMI and compared tissue plasminogen activator with placebo, and an early invasive with an early conservative strategy (9). Patients received what was then considered
2 104S Nissen JACC Vol. 41, No. 4 Suppl S Abbreviations and Acronyms ACS acute coronary syndrome(s) CAD coronary artery disease EEM external elastic membrane GP glycoprotein IVUS intravascular ultrasound MMP matrix metalloproteinase NSTEMI non ST-segment elevation myocardial infarction PCI percutaneous coronary intervention PPAR peroxisome proliferator-activated receptor RR remodeling ratio optimal medical therapy, including a beta-blocker, a shortacting calcium channel antagonist, nitrates, unfractionated heparin, and aspirin. In the tissue plasminogen activator versus placebo comparison, there were no significant differences in the six-week incidence of death, MI, or failure of initial therapy. Similarly, no differences were found between the invasive-versus-conservative arms in the six-week incidence of death, MI, or a poor performance on an exercise test (symptom-limited). However, patients treated with an aggressive strategy had significantly less recurrent ischemia requiring repeat hospitalization and needed fewer antianginal medications. Conversely, the Veterans Affairs Non Q-Wave Infarction Strategies in-hospital (VANQWISH) trial suggested that an aggressive approach might actually worsen outcomes. This study randomized 920 NSTEMI patients to an early invasive or early conservative strategy (10). At hospital discharge, the invasive-strategy arm was associated with significantly higher rates of death (26% vs. 12%; p 0.004) or non-fatal MI (15% vs. 4.9%; p 0.007). These differences persisted to one month and one year. The Fragmin and Fast Revascularization during InStability in Coronary artery disease (FRISC) II trial randomized 2,457 chest-pain patients with electrocardiographic changes or positive enzymes to the low-molecular-weight heparin, dalteparin, or placebo with either an invasive or conservative strategy (11). Stents were utilized in about two-thirds of PCI patients in both the invasive and conservative arms. At six months, there were no significant differences between dalteparin- and placebo-treated patients. However, death or MI was more common in the conservative than in the invasive group (12.1% vs. 9.4%; p 0.03). Angina severity and need for re-admission were also less common in the invasive arm. CONTEMPORARY TRIALS TACTICS. The Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy (TACTICS) TIMI-18 study was organized to try to confirm whether an invasive approach was superior to a conservative strategy using contemporary pharmacotherapy and intervention techniques (12). All 2,220 NSTEMI/ACS patients received aspirin, heparin, and the GP IIb/IIIa inhibitor, tirofiban. In the invasive arm, angiography was performed 4 to 48 h after randomization. Revascularization was performed in 60% of patients in the invasive arm and 36% in the conservative arm, with at least one stent deployed in approximately 85% of PCIs. Medications included beta-blockers (82%), nitrates (94%), and lipidlowering agents (52%). The TACTICS TIMI-18 was the first contemporary trial to demonstrate a modest benefit from an angiographically-guided approach. The triple end point of death, non-fatal MI, or re-admission for ischemia at six months was significantly lower in the aggressive than in the conservative arm (15.9% vs. 19.4%; p 0.025). The double end point of death or MI was also lower, but only marginally, in the invasive arm (7.3% vs. 9.5%; p 0.05). Surprisingly, however, the two-thirds of patients taking prophylactic aspirin and the 59% of troponin T-negative patients ( 0.1 ng/ml) showed little or no benefit from early invasive treatment. Furthermore, the 62% of subjects without ST-segment changes showed a slightly worse primary end point with early invasive strategy. Only the highest-risk ACS patients appeared to benefit, even with the use of GP IIb/IIIa inhibitor and stenting. Limitations of interventional strategies. STENOSIS EVAL- UATION USING ANGIOGRAPHY. Although coronary angiography is the gold standard for defining coronary anatomy, radiographic imaging depicts only a rather poor representation of cross-sectional coronary anatomy from a simple planar silhouette or luminogram of the contrast-filled lumen. Angiography is confounded by observer variability, with differences in the estimation of stenosis severity approaching 50% (13,14). Also, functional testing often reveals discordance between the severity of angiographic lesions and physiologic effects (15,16). Necropsy studies and intravascular ultrasound (IVUS) demonstrate that coronary lesions, particularly after plaque rupture, are complex, with distorted luminal shapes (17) that are difficult to assess using a planar angiographic silhouette (Fig. 1). Nevertheless, operators usually choose not to treat stenoses that do not appear hemodynamically significant, reserving intervention and PCI for visually severe lesions. However, intervention after plaque rupture and thrombosis is not without hazard. Embolization and no-reflow phenomena after successful angiographic intervention may lead to complications resulting in myocardial necrosis, unquestionably making some patients worse. Trial data provide ample evidence that the limitations of angiography result in inappropriate treatment of lesions, resulting in adverse outcomes. Twice as many trial patients have undergone revascularization in early-invasive than in ischemia-guided arms. As mentioned above, TACTICS patients without ST-segment changes actually fared worse with an early invasive approach, despite receiving upstream GP IIb/IIIa inhibitors. Also, patients in the VANQWISH
3 JACC Vol. 41, No. 4 Suppl S Nissen 105S Figure 1. Angiogram of complex lesion of right coronary artery. Several features make this artery difficult to evaluate by angiography. The lesion is complex with a bulbous projection that is difficult to quantitate. In addition, there is uncertainty regarding which segment to consider normal for comparative purposes. trial who were treated aggressively had a threefold increase in non-fatal MIs. THE DIFFUSE NATURE OF THE DISEASE. Angiography may also underestimate the extent of atherosclerosis (18,19). Both imaging and necropsy studies demonstrate that coronary artery disease (CAD) is rarely focal and typically involves a large portion of the arterial tree at the time of diagnosis (20,21). Indeed, with the appearance of the first Figure 2. Coronary remodeling concealing extensive disease. Intravascular ultrasound cross-sections from four sites (A, B, C, and D) are shown. At each site, there is extensive atherosclerosis, but without luminal encroachment. Comparing lumen size from the least diseased segment, D, to the most diseased segments, A and B, there is no change in lumen size.
4 106S Nissen JACC Vol. 41, No. 4 Suppl S Figure 3. Diffuse disease masquerading as a normal artery. Two sites, A and B, are shown by intravascular ultrasound. At both sites, a diffuse, concentric and symmetrical plaque involves the entire vessel circumference, giving the false appearance of a normal artery. luminal irregularity, at least 80% of the coronary tree is already atherosclerotic. Angiographic assessment is confounded by a phenomenon known as coronary remodeling (22), which consists of outward displacement of the external elastic membrane (EEM) in atherosclerotic segments, opposing luminal encroachment and concealing the presence of disease (Fig. 2). Lesion assessment requires a comparison of the luminal diameter with an adjacent, normal reference segment. Because coronary atherosclerosis is usually diffuse, however, there may be no truly normal segment from which to determine diameter reduction. In the presence of diffuse disease, percent stenosis will always underestimate the severity of the disease. In extreme examples, the entire vessel may be symmetrically narrowed, appearing as a small artery with minimal irregularities (Fig. 3). Therefore, exclusive focus on a culprit stenosis ignores the diffuse nature of the atherosclerotic disease process. IMPORTANCE OF THE NON-STENOTIC LESION. Abundant evidence demonstrates that high-grade stenoses ( 70% obstruction) are rarely the source of ACS and that coronary occlusion and MI evolve most frequently from plaques that are only mildly to moderately obstructive on angiography (23). In clinical trials, about 20% of ACS patients undergoing early angiography exhibit no hemodynamically significant stenosis (24). Furthermore, because intra-lesional thrombus contributes to the severity of stenosis, delayed angiography often shows a less severe stenosis after an underlying thrombus has been resolved. In most clinical trials, a delay in angiography resulted in a reduction in the number of patients who underwent PCI. Figure 4. Positive remodeling in a ruptured plaque. A ruptured plaque (right) is shown, along with a relatively normal adjacent reference segment (left). In the right panel, an interruption of the fibrous cap can be seen with exposure of the underlying lipid core. Compared with the normal reference segment, the external elastic membrane (EEM) area is considerably larger in the segment with plaque rupture than in the adjacent normal reference segment.
5 JACC Vol. 41, No. 4 Suppl S Nissen 107S Figure 5. The non-stenotic lesion as culprit. A patient with unstable angina was examined by coronary angiography and intravascular ultrasound (IVUS). The right coronary angiogram (far left, top panel) shows a right coronary artery lesion that was subsequently stented (far left, bottom panel). The IVUS examination of the mildly diseased left circumflex (middle panel) reveals a site (black arrow) that by IVUS (far right panel) shows a fresh plaque rupture (cavity from 12 to 2 o clock). The relationship between minimally obstructive stenoses and MI initially suggested that ACS evolves from the rupture of small, early atheromatous plaques. Recently, evidence from IVUS has offered a more complete explanation in stable versus unstable syndromes (25). We performed IVUS before coronary intervention in unstable (n 85) and stable (n 46) angina patients. A remodeling ratio (RR) was defined as the ratio of the EEM area at the lesion to that at the proximal reference site. Positive remodeling was defined as an RR 1.05 and negative remodeling as an RR Surprisingly, plaque area (13.9 vs mm 2 ;p 0.005), EEM area (16.1 vs mm 2 ;p 0.004), and the RR (1.06 vs mm 2 ;p 0.008) were significantly greater at culprit lesions in patients with unstable syndromes. Positive remodeling was more frequent in unstable than in stable lesions (51.8% vs. 19.6%; p 0.001) (Fig. 4). Inflammation may be a common pathophysiologic link underlying the association between plaque vulnerability and remodeling. An IVUS and histologic study of the human femoral arteries showed an association between histologic markers associated with plaque inflammation and positive arterial remodeling (26). Comparative analysis of the preatherectomy ultrasound images and histology of the plaque tissue demonstrated an association between positive remodeling and intense stromolysin staining (an enzyme associated with degradation of the fibrous cap) (27), suggesting that degradation of the extracellular matrix plays a role in arterial remodeling. Because bulky, non-stenotic lesions cause many, if not most, infarctions, the most severely stenotic lesion may not invariably be the culprit. Numerous ACS/NSTEMI patients have been identified in whom a comparatively minor stenotic lesion, distant from a ruptured plaque, was the apparent culprit lesion (Fig. 5). The morphologic characteristics of the vulnerable lesion are clearly more important in plaque vulnerability than percent stenosis. Plaque echolucency, which represents the lipid content of plaques, and a thin fibrous cap have been associated with ACS (28). Stable plaques characteristically have thick fibrous caps and small lipid cores. Fibrotic changes and vessel shrinkage, while causing more severe luminal stenosis, may render lesions more resistant to rupture. Multiplicity of vulnerable plaques. Angioscopic and angiographic studies have identified lesions with characteristics associated with plaque vulnerability at sites other than the culprit lesion in ACS patients (29,30). Although rupture of a vulnerable atheroma is the major cause of ACS/ NSTEMI, recent reports suggest that most ruptures are clinically silent and only occasionally cause acute symptoms (31). Presumably, after a rupture, the local balance between thrombosis and spontaneous thrombolysis prevents vessel occlusion. Recent evidence of a systemic inflammatory component also suggests that multiple sites are at risk for plaque rupture (32). We hypothesized that ACS patients would exhibit more extensive plaque vulnerability, manifested by lesion ulceration, at sites other than the culprit lesion. We therefore examined the prevalence of ulcerated atherosclerotic lesions in vessel segments adjacent to culprit lesions in patients with stable versus those with unstable syndromes. Postinterventional IVUS examinations were performed in patients treated with emergent stenting for acute MI. Control
6 108S Nissen JACC Vol. 41, No. 4 Suppl S Figure 6. Coronary disease in a 33-year-old transplant donor. The left anterior descending (left) and circumflex (right) show significant atherosclerosis in a previously asymptomatic young man who was a transplant donor after a motor vehicle accident. patients were treated with elective stenting for either stable or unstable angina. Plaque ulceration distant from the infarct site was significantly more prevalent in the post-mi than the angina group (19% vs. 4%) (Schoenhagen P, et al., unpublished data). These observations may explain the extraordinary difference in prognosis between patients with ACS/NSTEMI and chronic stable angina patients. Annual rates of death and MI average about 2% in chronic stable angina. The TACTICS trial, however, demonstrated a combined risk of death, non-fatal MI, and rehospitalization of approximately 16% at six months in ACS patients. Although the angiographically guided approach to ACS assumes that the focal Figure 7. Prevalence of coronary disease in transplant donors. These data demonstrate an aggressive increase in the likelihood of an atheroma of at least 0.5 mm in thickness in individuals as young as 13 years of age. yrs. years. Tuzcu EM, Kapadia SR, Tutar E, et al High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001;103: Adapted with permission from Lippincott, Williams, and Wilkins. lesion responsible for the unstable presentation can be readily identified and treated, this assumption is not invariably true. Early onset of the systemic process. Although CAD patients typically become symptomatic after age 40, atherosclerotic changes in the vessel wall begin early in life (33 35). Gross inspection of coronaries of the American soldiers killed in the Korean and Vietnam wars demonstrated atherosclerosis in 77% and 45% of autopsies, respectively. In the Bogalusa Heart Study, the prevalence of CAD in 15-year-old children was 8%, reaching 69% in adults 26 to 40 years old. Recently, we used IVUS in 262 heart transplant recipients to determine the presence, extent, and distribution of atherosclerosis in donor coronaries within weeks of transplantation (36). This method was designed to characterize the early atherosclerotic process, reflecting the fact that most donors are relatively young (Fig. 6). Donor atherosclerotic lesions were present in 136 patients, or 51.9% (Fig. 7). The prevalence of atherosclerosis varied from 17% in individuals 20 years old to 85% in subjects 50 years old. Because remodeling is evident in many early lesions, the lumen is usually preserved at first. Few lesions were detected by angiography, with stenoses identified in only 8% of patients. No abnormal angiograms were found in patients 30 years old, yet 28% of them had ultrasound evidence of atherosclerosis. If young healthy transplant donors have extensive atherosclerosis, it is not difficult to imagine the plaque burden in patients with an ACS. Accordingly, it seems unrealistic to expect the placement of a stent in a culprit lesion to significantly alter a process that began decades earlier and
7 JACC Vol. 41, No. 4 Suppl S Nissen 109S Figure 8. Plaque rupture by intravascular ultrasound (IVUS). Two adjacent sites in the coronary artery of a patient with an acute myocardial infarction are shown. In the right panel, the IVUS catheter is in a small lumen separated by a fibrous cap from a large lipid core. In this example, the lipid core is no longer present, and there is blood flow through the center of this atherosclerotic plaque. In the left panel, rupture of the fibrous cap can be seen at approximately 12 o clock, and the underlying lipid core has apparently escaped after plaque rupture. involves most of the coronary arterial tree. A metabolic approach is the only strategy able to affect the behavior of both the small number of angiographically visible lesions and the large number of occult, extraluminal plaques that will ultimately result in future coronary events. Plaque progression and vulnerability. The formation of atherosclerotic lesions is initiated by the recruitment of mononuclear leukocytes to the intima by adhesion molecules expressed on the surface of vascular endothelial cells (37). Chemoattractants facilitate entry into the intima, where macrophages accumulate lipid to become foam cells. A large, often eccentric, lipid pool forms, separated from the lumen by a fibrous cap (38). Positive remodeling, the outward expansion of the vessel at the lesion site, allows plaque accumulation without lumen obstruction (22). The accumulation of inflammatory cells and the changes in extracellular matrix macromolecules contribute to the changes in vascular morphology (39,40). These atheromata may remain silent for decades (41). Incompletely understood triggers may then initiate changes that lead to rupture and an ACS (42). The border between the fibrous cap and normal vessel wall at the edge of a large lipid core (the so-called shoulder area ) is particularly prone to rupture (43) (Fig. 8). The tensile strength of the fibrous cap depends on a balance between collagen biosynthesis by smooth muscle cells and collagen degradation by members of several proteinase families and their endogenous inhibitors (44,45). The secretion of these proteinases is induced by the accumulation and activation of macrophages and other inflammatory cells (46). Matrix-metalloproteinases (MMPs) play a central role in the degradation of the extracellular matrix of the fibrous cap (47). When a plaque ruptures, platelets that accumulate on exposed plaque increase expression of the GP IIb/IIIa receptor complex, initiating further platelet aggregation and fibrin deposition and eventually forming a luminal thrombus (48). The eventual thrombus size is determined by the balance between the prothrombotic milieu and local, intrinsic thrombolytic activity. Some of these episodes of plaque rupture are clinically symptomatic, but most are silent. Further plaque development is characterized by fibrosis, leading to a thick fibrous cap and a small lipid core (45) (Fig. 9). Fibrotic changes and vessel shrinkage, while causing more severe luminal stenosis, render lesions more resistant to rupture and can be regarded as part of a healing process. The progression of lesions through repeated cycles of vulnerability and rupture, with subsequent lesion stabilization, is probably a common pattern. If future events are to be avoided, atheroma formation, inflammation and rupture must be prevented. There is already evidence that lipid-lowering therapies can interrupt the atherosclerotic disease process, significantly influencing outcome in ACS patients. Lipid-lowering and plaque progression. Percutaneous coronary intervention reduces the severity of angina by improving coronary blood flow in the target vessel. However, the effect of lipid-lowering agents on cardiac events is far greater than their effect on the severity of angiographic stenosis (49,50). Imaging studies have confirmed in vivo
8 110S Nissen JACC Vol. 41, No. 4 Suppl S Figure 9. Stable and vulnerable coronary atheromata. In the left panel, a lesion with a thick fibrous core and small lipid core is illustrated. The right panel shows a lesion in a different patient with a thin fibrous cap and a large lipid core. The left hand plaque might be termed stable and the right hand plaque vulnerable based on pathological criteria. that statin therapy reduces plaque size and may change plaque composition without substantial changes in luminal area (20,51), suggesting that lipid-lowering therapy may regress or stabilize lipid-rich lesions. Unlike PCI, systemic therapies treat all of the potentially vulnerable plaques in the coronary arteries, not simply the focal lesion responsible for the ACS. Statins do not substantially change luminal area, but they decrease the incidence of death and MI by stabilizing atherosclerotic plaques throughout the coronary bed. A small IVUS study examined the progression of atherosclerosis after three years of treatment with pravastatin or diet in mildly diseased coronaries (52). During follow-up, plaque area increased by 41% in the control group but decreased by 7% in the treatment group. In a more recent serial IVUS study, patients (n 131) were randomized to treatment with high-dose atorvastatin or usual care, which could include statin therapy (51). After 12 months, mean low-density lipoprotein-cholesterol was reduced from 155 to 86 mg/dl in the atorvastatin group and from 166 to 140 mg/dl in the usual-care group. Mean absolute plaque volume showed a larger but insignificant increase in the usual-care group compared with the atorvastatin group (9.6 mm 3 vs mm 3 ). Plaque echogenicity increased to a larger extent in the atorvastatin group than in the usual-care group. Larger, ongoing serial regression-progression trials include the Reversal of Atherosclerosis with Aggressive Lipid lowering (REVERSAL) trial, which is comparing two lipid-lowering regimens, and the Norvasc for Regression of Manifest Atherosclerotic Lesions (NORMALISE) trial, which is evaluating amlodipine versus enalapril, or placebo (50). The primary end point of these trials is plaque burden, not lumen size. Although the relationship between changes in plaque burden and clinical events remains to be established, the potential of anti-atherosclerotic therapies to limit plaque growth or induce regression is very promising. Lipid lowering and plaque stability The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial randomized 3,086 patients with ACS or NSTEMI to atorvastatin (80 mg/day) or placebo initiated 24 to 96 h after hospital admission. In the atorvastatin group, mean low-density lipoprotein cholesterol declined from 124 mg/dl (3.2 mmol/l) to 72 mg/dl (1.9 mmol/l). The primary end point (16 weeks) was death, non-fatal acute MI, cardiac arrest with resuscitation, or recurrent symptomatic myocardial ischemia with objective evidence and requiring emergency rehospitalization. A primary end point event occurred in 228 patients (14.8%) in the atorvastatin group and 269 patients (17.4%) in the placebo group (relative risk, 0.84; 95% confidence interval, 0.70 to 1.00; p 0.048). There were fewer strokes in the atorvastatin group than in the placebo group (12 vs. 24 events; p 0.045). How might anti-atherosclerotic therapy improve early outcomes in ACS? Benefits are probably not derived strictly through regression of fixed stenoses (49). Libby and colleagues has demonstrated that a low-fat diet or treatment with lipid-lowering agents can reduce macrophage numbers and MMPs and increase collagen contents, thereby limiting oxidized low-density lipoprotein in the vessel wall and limiting the transformation of plaques to an unstable morphology (53 55). In experimental animals, a low-cholesterol
9 JACC Vol. 41, No. 4 Suppl S Nissen 111S diet reduced both the amount and activity of tissue factor, the most thrombogenic component of plaques. Lowering lipids also reduces expression of noxious inflammatory stimuli (i.e., interferon, tumor necrosis factor) that have the potential to destabilize the atheroma and influence vasomotor tone through effects on nitric oxide synthase (55). In experimental animals, statins reduce macrophage accumulation, inflammation, and proteolytic activity (54). Similarly, a study of primates treated with statins found decreased coronary vasomotor tone and reduced numbers of intimal and medial macrophages (54). The profound effects of anti-atherosclerotic therapies on plaque morphology and behavior render such treatments ideal for ACS patients. Reductions in atheroma inflammation, collagen degradation, tissue factor expression, and vasomotor tone have the potential to treat not only a single lesion, as in PCI, but also the entire systemic disease process. Entirely new classes of atherosclerosis-modulating therapies are under development, including agonists of the peroxisome proliferator-activated receptor (PPAR) system, including PPAR alpha agents that modulate lipid metabolism and PPAR gamma agonists that modulate both lipid and glucose metabolism. New anti-atherosclerotic therapies include inhibitors of acyl-coa:cholesterol O-acyltransferase that prevent accumulation of cholesterol ester in the macrophage, and inhibitors of cholesterol ester transfer protein that can raise high-density lipoprotein cholesterol by 50% or more. Ultimately, medical therapy and PCI should be considered as complementary rather than opposing strategies in the treatment and management of atherosclerosis and ACS. Patients are likely to benefit to the greatest extent from intervention when it is performed in combination with aggressive medical therapy. Reprint requests and correspondence: Dr. Steven E. Nissen, The Cleveland Clinic Foundation, F15, 9500 Euclid Avenue, Cleveland, Ohio Nissens@.ccf.org. REFERENCES 1. National Center for Health Statistics. Detailed diagnoses and procedures: National Hospital Discharge Survey, Hyattsville, MD: National Center for Health Statistics; 1998:13; data from Vital and Health Statistics. 2. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349: Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330: Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors: Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999;341: Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: Schwartz GG, Olsson AG, Ganz P, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 2001;285: Cohen M, Demers C, Gurfinkel EP, et al. A comparison of lowmolecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non Q-wave Coronary Events Study Group. N Engl J Med 1997;337: Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non Qwave myocardial infarction. Results of the TIMI IIIB trial. Thrombolysis In Myocardial Ischemia. Circulation 1994;89: Boden WE, O Rourke RA, Crawford MH, et al. Outcomes in patients with acute non Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998;338: FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354: Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344: Zir LM, Miller SW, Dinsmore RE, Gilbert JP, Harthorne JW. Interobserver variability in coronary angiography. Circulation 1976;53: Galbraith JE, Murphy ML, Desoyza N. Coronary angiogram interpretation: interobserver variability. JAMA 1981;240: White CW, Wright CB, Doty DB, et al. Does visual interpretation of the coronary arteriogram predict the physiologic importance of a coronary stenosis? N Engl J Med 1984;310: Kern MJ, Donohue TJ, Aguirre FV, et al. Assessment of angiographically intermediate coronary artery stenoses using the Doppler flow wire. Am J Cardiol 1993;71:26D 33D. 17. Waller BF. Crackers, breakers, stretchers, drillers, scrapers, shavers, burners, welders, and melters: the future treatment of atherosclerotic coronary artery disease? A clinical morphologic assessment. J Am Coll Cardiol 1989;13: Roberts WC, Jones AA. Quantitation of coronary arterial narrowing at necropsy in sudden coronary death. Am J Cardiol 1979;44: Vlaodaver Z, French R, van Tassel RA, Edwards JE. Correlation of the antemortem coronary angiogram and the postmortem specimen. Circulation 1973;47: Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001;104: Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995;92: Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316: Little WC, Constantinescu M, Applegate RJ, et al. Can arteriography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988;78: Braunwald E, Antman AM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non STsegment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Card 2000;36: Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 2000;101: Pasterkamp G, Schoneveld AH, van der Wal AC, et al. Relation of arterial geometry to luminal narrowing and histologic markers for
10 112S Nissen JACC Vol. 41, No. 4 Suppl S plaque vulnerability: the remodeling paradox. J Am Coll Cardiol 1998;32: Schoenhagen P, Vince DG, Ziada K, et al. Increased presence of matrix-metalloproteinase 3 in human coronary lesions with positive arterial remodeling (abstr). J Am Coll Cardiol 2000;35 Suppl A:58A 9A. 28. Yamagishi M, Terashima M, Awano K, et al. Morphology of vulnerable coronary plaque: insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. J Am Coll Cardiol 2000;35: Asakura M, Ueda Y, Yamaguchi O, et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Am Coll Cardiol 2001;37: Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000;343: Newby AC, Libby P, van der Wal A. Plaque instability the real challenge for atherosclerosis research in the next decade? Cardiovasc Res 1999;41: Ridker PM. Role of Inflammatory biomarkers in prediction of coronary heart disease Lancet 2001;358: Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea: preliminary report. JAMA 1953;152: McNamara JJ, Molot MA, Stremple JF, et al. Coronary artery disease in combat casualties in Vietnam. JAMA 1971;216: Berenson GS, Wattigney WA, Tracy RE, et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (the Bogalusa Heart Study). Am J Cardiol 1992;70: Tuzcu EM, Hobbs RE, Rincon G, et al. Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation: insights from intravascular ultrasound. Circulation 1995;91: Frenette P, Wagner D. Adhesion molecules. N Engl J Med 1996;334: Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983;50: Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 1976;295: Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 1976;295: Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001;103: Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92: Loree HM, Kamm RD, Stringfellow RG, et al. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res 1992;71: Amento EP, Ehsani N, Palmer H, et al. Cytokines positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Atherosclerosis 1991;11: Small DM, Bond MG, Waugh D, et al. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest 1984;73: Lendon CL, Davies MJ, Born GV, et al. Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis 1991;87: Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94: Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984;310: Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87: Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91: Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001;104: Takagi T, Yoshida K, Akasaka T, et al. Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin. Am J Cardiol 1997;79: Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma. Circulation 1998;97: Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998;31: Libby P, Aikawa M. New insights into plaque stabilization by lipid lowering. Drugs 1998;56 Suppl 1:9 13.
2003 by the American College of Cardiology Foundation ISSN /03/$30.00
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. PII S0735-1097(02)02688-8
More informationPathology of Coronary Artery Disease
Pathology of Coronary Artery Disease Seth J. Kligerman, MD Pathology of Coronary Artery Disease Seth Kligerman, MD Assistant Professor Medical Director of MRI University of Maryland Department of Radiology
More informationTitle for Paragraph Format Slide
Title for Paragraph Format Slide Presentation Title: Month Date, Year Atherosclerosis A Spectrum of Disease: February 12, 2015 Richard Cameron Padgett, MD Executive Medical Director, OHVI Pt RB Age 38
More informationPharmacologic Therapy of Coronary Disease
Pharmacologic Therapy of Coronary Disease M. MOHSEN IBRAHIM, MD Prof. of Cardiology- Cairo University President of the Egyptian Hypertension Society Introduction Coronary artery disease (CAD) is possibly
More informationRelationship Between Atheroma Regression and Change in Lumen Size After Infusion of Apolipoprotein A-I Milano
Journal of the American College of Cardiology Vol. 47, No. 5, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.11.040
More informationIVUS Virtual Histology. Listening through Walls D. Geoffrey Vince, PhD The Cleveland Clinic Foundation
IVUS Virtual Histology Listening through Walls D. Geoffrey Vince, PhD Disclosure VH is licenced to Volcano Therapeutics Grant funding from Pfizer, Inc. Grant funding from Boston-Scientific Most Myocardial
More informationQuinn Capers, IV, MD
Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular
More information12/18/2009 Resting and Maxi Resting and Max mal Coronary Blood Flow 2
Coronary Artery Pathophysiology ACS / AMI LeRoy E. Rabbani, MD Director, Cardiac Inpatient Services Director, Cardiac Intensive Care Unit Professor of Clinical Medicine Major Determinants of Myocardial
More informationVulnerable Plaque Pathophysiology, Detection, and Intervention. VP: A Local Problem or Systemic Disease. Erling Falk, Denmark
Vulnerable Plaque Pathophysiology, Detection, and Intervention VP: A Local Problem or Systemic Disease Erling Falk, Denmark Vulnerable Plaque Pathophysiology, Detection, and Intervention VP: A Local Problem
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationThe PROSPECT Trial. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque
The PROSPECT Trial Providing Regional Observations to Study Predictors of Events in the Coronary Tree A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively
More informationIschemic heart disease
Ischemic heart disease Introduction In > 90% of cases: the cause is: reduced coronary blood flow secondary to: obstructive atherosclerotic vascular disease so most of the time it is called: coronary artery
More informationChanges in Coronary Plaque Color and Morphology by Lipid-Lowering Therapy With Atorvastatin: Serial Evaluation by Coronary Angioscopy
Journal of the American College of Cardiology Vol. 42, No. 4, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00770-8
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More information2003 by the American College of Cardiology Foundation ISSN /03/$30.00
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02963-7
More informationGary S. Mintz,, MD. IVUS Observations in Acute (vs Chronic) Coronary Artery Disease: Structure vs Function
Gary S. Mintz,, MD IVUS Observations in Acute (vs Chronic) Coronary Artery Disease: Structure vs Function Important IVUS Observations: Remodeling Originally used (first by Glagov) ) to explain atherosclerosis
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationInvasive Coronary Imaging Modalities for Vulnerable Plaque Detection
Invasive Coronary Imaging Modalities for Vulnerable Plaque Detection Gary S. Mintz, MD Cardiovascular Research Foundation New York, NY Greyscale IVUS studies have shown Plaque ruptures do not occur randomly
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationBy Graham C. Wong, MD; and Christian Constance, MD. therapy in reducing long-term cardiovascular
Lipid-Lowering Therapy For Acute Coronary Syndromes There is a large amount of evidence that supports the early use of statins in the treatment of acute coronary syndromes. The anti-inflammatory, anti-thrombotic
More informationAssessment of plaque morphology by OCT in patients with ACS
Assessment of plaque morphology by OCT in patients with ACS Takashi Akasaka, M.D. Department of Cardiovascular Medicine Wakayama, Japan Unstable plaque Intima Lipid core Plaque rupture and coronary events
More informationImaging Overview for Vulnerable Plaque: Data from IVUS Trial and An Introduction to VH-IVUS Imgaging
Imaging Overview for Vulnerable Plaque: Data from IVUS Trial and An Introduction to VH-IVUS Imgaging Gary S. Mintz,, MD Cardiovascular Research Foundation New York, NY Today, in reality, almost everything
More informationAcute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
More informationImaging Atheroma The quest for the Vulnerable Plaque
Imaging Atheroma The quest for the Vulnerable Plaque P.J. de Feijter 1. Department of Cardiology 2. Department of Radiology Coronary Heart Disease Remains the Leading Cause of Death in the U.S, Causing
More informationCoronary Artery Thermography
Coronary Artery Thermography The 10th Anniversary, Interventional Vascular Therapeutics Angioplasty Summit 2005 TCT Asia Pacific Christodoulos Stefanadis Professor of Cardiology Athens Medical School In
More informationORIGINAL CONTRIBUTION. Risk of Developing Coronary Artery Disease Following a Normal Coronary Angiogram in Middle-Aged Adults
ORIGINAL CONTRIBUTION Risk of Developing Coronary Artery Disease Following a Normal Coronary Angiogram in Middle-Aged Adults Maheswara S.G. Rao Golla, MBBS 1 ; Timir Paul, MD 2 ; Siddhartha Rao, MD 1 ;
More informationChapter 43 Noninvasive Coronary Plaque Imaging
hapter 43 Noninvasive oronary Plaque Imaging NIRUDH KOHLI The goal of coronary imaging is to define the extent of luminal narrowing as well as composition of an atherosclerotic plaque to facilitate appropriate
More informationEAE Teaching Course. Magnetic Resonance Imaging. Competitive or Complementary? Sofia, Bulgaria, 5-7 April F.E. Rademakers
EAE Teaching Course Magnetic Resonance Imaging Competitive or Complementary? Sofia, Bulgaria, 5-7 April 2012 F.E. Rademakers Complementary? Of Course N Engl J Med 2012;366:54-63 Clinical relevance Treatment
More informationAcute Myocardial Infarction. Willis E. Godin D.O., FACC
Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable
More informationAdded Value of Invasive Coronary Imaging for Plaque Rupture and Erosion
Assessment of Coronary Plaque Rupture and Erosion Added Value of Invasive Coronary Imaging for Plaque Rupture and Erosion Yukio Ozaki, MD, PhD, FACC, FESC Cardiology Dept., Fujita Health Univ. Toyoake,
More informationIntravascular Ultrasound
May 2008 Beth Israel Deaconess Medical Center Harvard Medical School Intravascular Ultrasound Matthew Altman, HMS III Gillian Lieberman, MD BIDMC Department of Radiology Presentation Overview 1. Patient
More informationObjectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?
Objectives Acute Coronary Syndromes; The Nuts and Bolts Michael P. Gulseth, Pharm. D., BCPS Pharmacotherapy II Spring 2006 Compare and contrast pathophysiology of unstable angina (UA), non-st segment elevation
More informationJournal of the American College of Cardiology Vol. 38, No. 1, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 1, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01315-8 Coronary
More informationMeasuring Natriuretic Peptides in Acute Coronary Syndromes
Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationPATHOPHYSIOLOGY OF ACUTE CORONARY SYNDROMES
PATHOPHYSIOLOGY OF ACUTE CORONARY SYNDROMES Brian R. Holroyd, MD, FACEP, FRCPC Professor and Director, Division of Emergency Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton,
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationChapter 2 Drug therapy or coronary angioplasty for the treatment of coronary artery disease: new insights
D RUG THERAPY VS CORONARY ANGIOPLASTY R EFERENCES Chapter 2 Drug therapy or coronary angioplasty for the treatment of coronary artery disease: new insights Giovanni Amoroso Ad J. Van Boven Harry J.G.M.
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationJournal of the American College of Cardiology Vol. 39, No. 10, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 39, No. 10, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01841-7
More informationThe Site of Plaque Rupture in Native Coronary Arteries
Journal of the American College of Cardiology Vol. 46, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.067
More informationRelationship Between Cardiovascular Risk Factors and Atherosclerotic Disease Burden Measured by Intravascular Ultrasound
Journal of the American College of Cardiology Vol. 47, No. 10, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.12.058
More informationIVUS Analysis. Myeong-Ki. Hong, MD, PhD. Cardiac Center, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea
IVUS Analysis Myeong-Ki Hong, MD, PhD Cardiac Center, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea Intimal disease (plaque) is dense and will appear white Media is made of
More informationCase study #1 Evolving Concepts in Non-ST Elevation ACS (NSTE-ACS)
Case study #1 Evolving Concepts in Non-ST Elevation ACS (NSTE-ACS) Fernando Bátiz MD PGY-5 cardiology fellow Hospital Español Fernando Bátiz fernando_batiz@me.com Sex: Female Race: Caucasian Age: 79 years
More informationThe PROSPECT Trial. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque
The PROSPECT Trial Providing Regional Observations to Study Predictors of Events in the Coronary Tree A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively
More informationChest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham
Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationactually rupture! Challenges to the vulnerable plaque concept
An Update on the Pathogenesis of the Acute Coronary Syndromes Peter Libby Brigham & Women s Hospital Harvard Medical School ADVANCES IN HEART DISEASE University of California San Francisco December 20,
More informationThe Severity of Coronary Atherosclerosis at Sites of Plaque Rupture With Occlusive Thrombosis
1138 MORPHOLOGIC STUDIES The Severity of Coronary Atherosclerosis at Sites of Plaque Rupture With Occlusive Thrombosis JIAN-HUA QIAO, MD, MICHAEL C. FISHBEIN, MD, FACC Los Angeles. California Atherosclerotic
More informationWho Cares About the Past?
Risk Factors, the New Calcium Score, Rheology and Atherosclerosis Progression Arthur Agatston 2/21/15 The Vulnerable Plaque vs. Plaque Burden CT Angiogram Is There a Role for Coronary Artery Calcium Scoring
More informationDiabetes and Occult Coronary Artery Disease
Diabetes and Occult Coronary Artery Disease Mun K. Hong, MD, FACC, FSCAI Director, Cardiac Catheterization Laboratory & Interventional Cardiology St. Luke s-roosevelt Hospital Center New York, New York
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationCoronary plaque erosion: a clinical case. Dr. Giampaolo Niccoli, MD, PhD, FESC Institute of Cardiology Catholic University, Rome, Italy
Coronary plaque erosion: a clinical case, MD, PhD, FESC Institute of Cardiology Catholic University, Rome, Italy Coronary plaque erosion: a clinical case B.M. Age: 59 years Sex: female. Cardiological risk
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationPathology of Vulnerable Plaque Angioplasty Summit 2005 TCT Asia Pacific, Seoul, April 28-30, 2005
Pathology of Vulnerable Plaque Angioplasty Summit 25 TCT Asia Pacific, Seoul, April 28-3, 25 Renu Virmani, MD CVPath, A Research Service of the International Registry of Pathology Gaithersburg, MD Plaque
More informationTiming of angiography for high- risk ACS
Timing of angiography for high- risk ACS Christian Spaulding, MD, PhD, FESC, FACC Cardiology Department Cochin Hospital, Inserm U 970 Paris Descartes University Paris, France A very old story. The Interventional
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationPrehospital and Hospital Care of Acute Coronary Syndrome
Ischemic Heart Diseases Prehospital and Hospital Care of Acute Coronary Syndrome JMAJ 46(8): 339 346, 2003 Katsuo KANMATSUSE* and Ikuyoshi WATANABE** * Professor, Second Internal Medicine, Nihon University,
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationJournal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00643-9 Early
More informationAcute Coronary Syndrome. ACC/AHA 2002 Guidelines
Acute Coronary Syndrome ACC/AHA 2002 Guidelines ACS Unstable Angina Non ST elevation MI ST elevation MI ACS UA and Non STEMI described in these guidelines Management of STEMI described in separate guidelines
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationTHE COMPLEX RELATION BETWEEN VULNERABILITY AND ISCHEMIA a paradigm shift
THE COMPLEX RELATION BETWEEN VULNERABILITY AND ISCHEMIA a paradigm shift Angioplasty Summit TCT ASIA Seoul, Korea, april 23rd, 2008 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands
More informationBenefit of Early Invasive Therapy in Acute Coronary Syndromes A Meta-Analysis of Contemporary Randomized Clinical Trials
Journal of the American College of Cardiology Vol. 48, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.06.050
More informationManagement of Multivessel CAD: Stenting or CABG?
Management of Multivessel CAD: Stenting or CABG? Filippos Triposkiadis, MD, FESC, FACC Department of Cardiology, University of Thessaly Long-term Outcome of Patients With 3VD Undergoing CABG A Report from
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationIntervention: How and to which extent is technology helping us?
Cardiological Society of India Congress 12th February 2016 Chennai, India Intervention: How and to which extent is technology helping us? SIMONE BISCAGLIA MD CARDIOVASCULAR INSTITUTE, FERRARA, ITALY Introduction
More informationMedicine Dr. Omed Lecture 2 Stable and Unstable Angina
Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Risk stratification in stable angina. High Risk; *post infarct angina, *poor effort tolerance, *ischemia at low workload, *left main or three vessel
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationCLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY. Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus
CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus OPTICAL COHERENCE TOMOGRAPHY (OCT) IVUS and OCT IVUS OCT
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationThe 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories
The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury
More informationIdentifying patients at risk: novel diagnostic techniques
European Heart Journal Supplements (2004) 6 (Supplement C), C15 C20 Identifying patients at risk: novel diagnostic techniques Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, OH, USA
More informationAcute coronary syndrome (ACS) is an
OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia
More informationCottrell Memorial Lecture. Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease?
Cottrell Memorial Lecture Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease? Stephen Nicholls MBBS PhD @SAHMRI_Heart Disclosures Research support: AstraZeneca,
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationCulprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome
Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,
More informationHeart disease is the major cause of death in
EPIDEMIOLOGY AND PATHOPHYSIOLOGY OF ACUTE CORONARY SYNDROME Kurt C. Kleinschmidt, MD, FACEP* ABSTRACT The high prevalence of heart disease puts many Americans at risk for an acute coronary attack. Their
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More information04RC2. The biology of vulnerable plaques. Jozef L. Van Herck 1, Christiaan J. Vrints 1, Arnold G. Herman 2
04RC2 The biology of vulnerable plaques Jozef L. Van Herck 1, Christiaan J. Vrints 1, Arnold G. Herman 2 1 Department of Cardiology, Antwerp University Hospital, Edegem, Belgium 2 Department of Pharmacology,
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationJournal of the American College of Cardiology Vol. 40, No. 6, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 40, No. 6, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02119-8
More informationCardiovascular Research Foundation and Columbia University Medical Center, New York.
Virtual Histology Intravascular Ultrasound Analysis of Non-culprit Attenuated Plaques Detected by Grayscale Intravascular Ultrasound in Patients with Acute Coronary Syndromes Xiaofan Wu, Akiko Maehara,
More informationProgression of coronary atherosclerosis may lead to angina
Regression of Coronary Atherosclerosis by Simvastatin A Serial Intravascular Ultrasound Study Lisette Okkels Jensen, MD, PhD; Per Thayssen, MD, DMSci; Knud Erik Pedersen, MD, DMSci; Steen Stender, MD,
More informationAnatomy is Destiny, But Physiology is Here Today
Published on Journal of Invasive Cardiology (http://www.invasivecardiology.com) September, 2010 [1] Anatomy is Destiny, But Physiology is Here Today Thu, 9/9/10-10:54am 0 Comments Section: Commentary Issue
More informationAcute coronary syndrome (ACS) is a potentially
DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD* ABSTRACT Acute coronary syndrome is a form of coronary artery disease and has a broad range of clinical presentations.
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationCardiovascular risk and therapeutic benefit of coronary interventions for patients with unstable angina according to the troponin T status
European Heart Journal (2000) 21, 1159 1166 doi:10.1053/euhj.1999.1986, available online at http://www.idealibrary.com on Cardiovascular risk and therapeutic benefit of coronary interventions for patients
More information대한심장학회춘계학술대회 Satellite Symposium
대한심장학회춘계학술대회 Satellite Symposium Coronary Plaque Regression and Compositional Changes by Lipid-Lowering Therapy: IVUS Substudy in Livalo (Pitavastatin) in Acute Myocardial Infarction Study (LAMIS) Livalo
More information